Sanofi American Depositary Receipt logo

Sanofi American Depositary Receipt (SNY)

Market Closed
8 Dec, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
48. 44
-1.09
-2.2%
After Hours
$
48. 69
+0.25 +0.52%
122.7B Market Cap
- P/E Ratio
8.15% Div Yield
2,604,998 Volume
- Eps
$ 49.53
Previous Close
Day Range
48.22 48.72
Year Range
44.62 60.12
Want to track SNY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 52 days
France considering stake in Sanofi's Opella, minister says

France considering stake in Sanofi's Opella, minister says

France is considering taking a stake in Sanofi's Opella arm, said finance minister Antoine Armand, to allay concerns that the French drugmaker's plans to sell a 50% stake in Opella to a U.S. private equity firm could result in job cuts.

Reuters | 1 year ago
Should Value Investors Buy Sanofi (SNY) Stock?

Should Value Investors Buy Sanofi (SNY) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 1 year ago
French government seeking job guarantees from Sanofi over Doliprane production sites

French government seeking job guarantees from Sanofi over Doliprane production sites

The French government is seeking job guarantees from drugmaker Sanofi regarding its Doliprane production sites in the event of a sale of its consumer health branch, Economy Minister Antoine Armand said on Monday.

Reuters | 1 year ago
Sanofi in talks to sell consumer healthcare business that makes Dulcolax

Sanofi in talks to sell consumer healthcare business that makes Dulcolax

Sanofi on Friday said it's in talks with the private equity firm CD&R to sell just over half of its consumer healthcare business, in a deal that could yield billions of dollars for the French drugmaker.

Marketwatch | 1 year ago
Sanofi in talks to sell 50% stake in consumer health business to CD&R

Sanofi in talks to sell 50% stake in consumer health business to CD&R

Sanofi has entered into discussions with U.S. private equity firm Clayton Dubilier & Rice to sell a controlling 50% stake in its consumer health business Opella, the French pharmaceutical giant said on Friday.

Reuters | 1 year ago
CD&R nears deal to buy Sanofi's consumer unit for $16 bln, Bloomberg News reports

CD&R nears deal to buy Sanofi's consumer unit for $16 bln, Bloomberg News reports

Private equity firm Clayton Dubilier & Rice (CD&R) is nearing a deal to acquire Sanofi's consumer health unit for about 15 billion euros ($16.4 billion), Bloomberg News reported on Thursday.

Reuters | 1 year ago
Denali-Sanofi scraps mid-stage study for multiple sclerosis drug

Denali-Sanofi scraps mid-stage study for multiple sclerosis drug

Drug developer Denali Therapeutics said on Thursday its partner Sanofi has discontinued a mid-stage study testing their experimental drug to treat multiple sclerosis as it failed to meet the main and secondary goals.

Reuters | 1 year ago
Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply, Bloomberg News reports

Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply, Bloomberg News reports

GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, Bloomberg News reported on Friday.

Reuters | 1 year ago
Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln

Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln

Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million.

Reuters | 1 year ago
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD

Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD

Sanofi and Regeneron's Dupixent becomes the first biologic treatment approved for COPD in the United States.

Zacks | 1 year ago
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD

Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD

Shares of Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) edged higher Friday after their chronic obstructive pulmonary disease (COPD) treatment received approval from the Food and Drug Administration (FDA).

Investopedia | 1 year ago
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease

FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease

On Friday, the FDA approved Regeneron Pharmaceuticals, Inc.  REGN and Sanofi SA's SNY Dupixent (dupilumab) as an add-on maintenance treatment of inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype, generally known as “smoker's lung.”

Benzinga | 1 year ago
Loading...
Load More